Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: Early prediction of chemosensitivity with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.. : FDG-PET/CT for luminal breast cancer

Archive ouverte

Groheux, David | Hatt, Mathieu | Hindié, Elif | Giacchetti, Sylvie | de Cremoux, Patricia | Lehmann-Che, Jacqueline | Martineau, Antoine | Marty, Michel | Cuvier, Caroline | Cheze Le Rest, Catherine | de Roquancourt, Anne | Visvikis, Dimitris | Espié, Marc

Edité par CCSD ; Wiley -

International audience. BACKGROUND: The objective of this prospective study was to evaluate the ability of (18) F-fluorodeoxyglucose ((18) F-FDG) positron emission tomography/computed tomography (PET/CT) to predict chemosensitivity in patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. METHODS: Sixty-four consecutive patients underwent (18) F-FDG PET/CT scanning at baseline and after the second course of neoadjuvant chemotherapy (NAC). The evolution (Δ) between the 2 scans of image parameters (maximum standardized uptake value [SUVmax ], SUVmean , metabolic tumor volume, and total lesion glycolysis [TLG]) was measured. Correlations between early changes in PET-derived parameters and pathologic response observed in surgical specimens after the completion of 8 courses of NAC were estimated with Mann-Whitney U tests. Response prediction on the basis of clinical data, histologic type, or molecular markers also was assessed (Fisher exact test). Receiver operating characteristic (ROC) analysis was used to compare the area under the curve (AUC) of each parameter. RESULTS: The best prediction of chemosensitivity was obtained with ΔTLG (-49% ± 31% in nonresponders vs -73% ± 25% in responders; P < .0001). Among the biologic parameters, only negative progesterone receptor status (57% responders vs 31% nonresponders; P = .04) and luminal B subtype (63% responders vs 22% nonresponders; P = .02) were predictive of a pathologic response. ROC analysis resulted in an AUC of 0.81, 0.73, 0.71, and 0.63 for ΔTLG, ΔSUVmax , luminal subtype, and progesterone receptor status, respectively. CONCLUSIONS: When patients responded to NAC, the majority of ER-positive/HER2 negative tumors exhibited partial tumor shrinkage; and the PET parameters that combined volume and activity measurements, such as TLG, offered better accuracy for early prediction than the SUVmax . Negative progesterone receptor status and luminal B subtype had weaker predictive power than PET-derived parameters. Cancer 2013;119:1960-1968. © 2013 American Cancer Society.

Suggestions

Du même auteur

Comparison Between 18F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer.

Archive ouverte | Hatt, Mathieu | CCSD

International audience. The goal of this study was to determine the best predictive factor among image-derived parameters extracted from sequential F-FDG PET scans for early tumor response prediction after 2 cycles ...

Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Archive ouverte | Groheux, David | CCSD

International audience. PURPOSE: The aim of this retrospective study was to determine if some features of baseline 18F-FDG PET images, including volume and heterogeneity, reflect clinical, histological or immunohist...

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Archive ouverte | Lehmann-Che, Jacqueline | CCSD

International audience. INTRODUCTION: Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally...

Chargement des enrichissements...